These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7583495)

  • 21. Social skills training for schizophrenic individuals at risk for relapse.
    Liberman RP; Mueser KT; Wallace CJ
    Am J Psychiatry; 1986 Apr; 143(4):523-6. PubMed ID: 2869704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium nitroprusside treatment of clozapine-refractory schizophrenia.
    Maia-de-Oliveira JP; Belmonte-de-Abreu P; Bressan RA; Cachoeira C; Baker GB; Dursun SM; Hallak JE
    J Clin Psychopharmacol; 2014 Dec; 34(6):761-3. PubMed ID: 25203464
    [No Abstract]   [Full Text] [Related]  

  • 23. [Atypical antipsychotic agents in the adolescent: what implications for the future?].
    Cohen D
    Encephale; 2011 Sep; 37(4 Suppl 4):H15-7. PubMed ID: 22108183
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Full circle-old drugs prove more beneficial than newer agents for schizophrenia: a case report.
    Veronin MA; Colson K; Roffman ME; Roman MW
    Issues Ment Health Nurs; 2012 Nov; 33(11):797-800. PubMed ID: 23146014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study.
    Kumazaki H; Kobayashi H; Niimura H; Kobayashi Y; Ito S; Nemoto T; Sakuma K; Kashima H; Mizuno M
    Compr Psychiatry; 2012 Oct; 53(7):946-51. PubMed ID: 22554765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
    Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
    Nasrallah H; Morosini P; Gagnon DD
    Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of "natural" course, relapse and prophylactic response in schizophrenic patients.
    Pietzcker A; Gaebel W
    Pharmacopsychiatria; 1983 Nov; 16(6):206-11. PubMed ID: 6141577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment and outcomes in adolescents with schizophrenia.
    Schulz SC; Findling RL; Friedman L; Kenny JT; Wise AL
    J Clin Psychiatry; 1998; 59 Suppl 1():50-4; discussion 55-6. PubMed ID: 9448669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The routine prescription: between references and reality].
    Lachaux B
    Encephale; 2006 Oct; 32(5 Pt 3):S873-4. PubMed ID: 17119491
    [No Abstract]   [Full Text] [Related]  

  • 33. Identifying schizophrenic patients who should not receive medication.
    Buckley P
    Schizophr Bull; 1982; 8(3):429-32. PubMed ID: 6127807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
    Harvey PD; Patterson TL; Potter LS; Zhong K; Brecher M
    Am J Psychiatry; 2006 Nov; 163(11):1918-25. PubMed ID: 17074943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
    Meltzer HY; Thompson PA; Lee MA; Ranjan R
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 37. Improving reliability of the assessment of the life course of schizophrenia.
    Thompson AH; Newman SC; Orn H; Bland RC
    Can J Psychiatry; 2010 Nov; 55(11):729-35. PubMed ID: 21070701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply to comments on "Optimizing early prediction for antipsychotic response in schizophrenia".
    Chang YC; Lane HY
    J Clin Psychopharmacol; 2009 Aug; 29(4):391. PubMed ID: 19593183
    [No Abstract]   [Full Text] [Related]  

  • 39. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current concepts of pharmacological treatment in schizophrenia].
    Jarema M
    Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.